I’ve been diagnosed with Ovarian Cancer , stage 3C in 2023. Had debulking surgery , chemotherapy and 22 Avastin...

I'm glad you're reaching out about this. Let me help you understand what's happening with your CA125 levels and lymph node findings, and then we can talk about what questions to ask your care team.

Understanding Your Current Situation

What CA125 Rising Means (Educational Context):

CA125 is a tumor marker—a protein that cancer cells often produce. According to the NCCN Guidelines for Ovarian Cancer, rising CA125 levels can suggest cancer activity, but it's not definitive on its own. Here's why your doctors are paying attention:

• Your CA125 has been climbing since July
• You had a complete response (no evidence of disease) after your initial treatment
• A 1cm lymph node appeared on your August CT scan

This pattern typically suggests recurrent disease—meaning the cancer may be returning after your initial treatment response.

How Doctors Think About This (Clinical Framework)

According to NCCN Guidelines, when patients show signs of recurrence, oncologists evaluate:

1. Disease-free interval: How long between your initial treatment and these new findings (about 7 months in your case)
2. Platinum sensitivity: Whether your cancer will likely respond to platinum-based chemotherapy again
3. Extent of recurrence: Is it limited (like one lymph node) or more widespread?

Your situation—recurrence after a good initial response—typically classifies you as having platinum-sensitive recurrent disease, which generally means your cancer may respond well to additional platinum-based chemotherapy.

What Treatment Options Generally Exist

For patients with platinum-sensitive recurrent ovarian cancer, NCCN Guidelines describe several approaches:

• Platinum-based chemotherapy (carboplatin, often combined with other drugs)
• PARP inhibitors (like olaparib, niraparib, or rucaparib)—especially if you have BRCA mutations or homologous recombination deficiency (HRD)
• Bevacizumab (Avastin) combined with chemotherapy
• Clinical trials testing newer combinations

Critical Questions to Ask Your Oncologist

However, YOUR specific situation requires your doctor's evaluation. Here are targeted questions:

1. "Do you confirm this is recurrent disease, and would you classify it as platinum-sensitive?" (This determines which treatments are most appropriate)

2. "Have you reviewed my BRCA1/2 status and HRD testing from my original diagnosis?" (This is crucial because PARP inhibitors work best for patients with these mutations or HRD-positive tumors—according to NCCN Guidelines, this testing should inform maintenance therapy decisions)

3. "What is your recommended treatment approach, and why?" (Ask them to explain the pros/cons of chemotherapy vs. PARP inhibitors vs. other options for my specific case)

4. "Should we do any additional molecular testing on my recurrent disease?" (NCCN Guidelines recommend tumor molecular testing for recurrent disease if not previously done, including testing for BRCA1/2, HRD status, and other markers)

5. "What is the goal of treatment—to extend remission, manage symptoms, or both?" (This helps clarify realistic expectations)

6. "Are there clinical trials I should consider?" (Especially important given your previous good response to treatment)

Important Context About Your Lymph Node

A 1cm lymph node is relatively small. According to NCCN Guidelines, the extent and location of recurrent disease significantly affects treatment planning. Your doctors will want to know:

• Is this the only site of recurrence, or are there other areas?
• Has imaging shown any other concerning findings?

This information shapes whether you're a candidate for surgery, systemic chemotherapy, or other approaches.

Next Steps

1. Request a formal recurrence discussion with your oncology team—ask them to explain their findings and recommended treatment plan
2. Ask about your molecular testing status from your original surgery/pathology
3. Request copies of your pathology report and any molecular testing results if you don't have them
4. Consider a second opinion at an NCCN Cancer Center if you want additional perspective (NCCN Guidelines emphasize that evaluation by a gynecologic oncologist is recommended for all ovarian cancer patients)

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

According to NCCN Guidelines for Ovarian Cancer (Version 3.2025), recurrent disease management depends on platinum sensitivity, BRCA/HRD status, and extent of disease. Your oncologist will determine the most appropriate approach for YOUR specific case based on your complete clinical picture, prior treatments, and current imaging/lab findings.